Last reviewed · How we verify
RO4998452
At a glance
| Generic name | RO4998452 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus (PHASE2)
- A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes (PHASE1)
- A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment (PHASE1)
- A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO4998452 CI brief — competitive landscape report
- RO4998452 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI